ADC Toxicity Summit 2025

Join 28bio at the 3rd ADC Toxicity Summit, the only industry-led event bringing together toxicology, pharmacology, translational science, and clinical development experts to accelerate bench-to-bedside-to-bench innovation by preventing, predicting, and mitigating toxicities to enhance ADC safety and clinical translation.

‍

Presentation

‍

Rethinking Peripheral Neuropathy Models: A Human Approach to Preclinical Testing

‍

Preclinical drug development often fails due to poor translation from animal models to human physiology. Peripheral neuropathy is difficult to assess using 2D cell cultures or animal models, as they fail to replicate 3D nerve structure and functional electrophysiology. To address this, 28bio developed PNS-3D technology, a human, complex in vitro organoid model designed for preclinical testing of disease-, medication-, and toxin-induced neuropathies.

‍

Poster

‍

Comparison of a 3D Nerve-on-a-Chip peripheral nerve model  to 2D neuronal assays for clinical translation with antibody drug conjugate (ADC) toxicity screening

‍

Chemotherapy-induced peripheral neuropathy (CIPN) is a major side effect of anticancer therapies, often leading to pain, sensory loss, and treatment discontinuation. Despite promising preclinical data, many compounds later show neurotoxicity in patients, including antibody-drug conjugates (ADCs). To address this, we developed microphysiological systems (MPS) using human iPSC-derived sensory neurons and Schwann cells in both 2D and 3D formats with PNS-3D technology enabling electrophysiological and imaging-based toxicity assessments. We tested four ADCs and MMAE to evaluate in vitro neurotoxicity across both systems.

‍

Schedule a Meeting

‍

‍